InvestorsHub Logo
Followers 4
Posts 753
Boards Moderated 0
Alias Born 04/18/2017

Re: None

Tuesday, 11/19/2019 12:23:55 AM

Tuesday, November 19, 2019 12:23:55 AM

Post# of 54915
Okay so EXAS sells Cologuard for around $480 per test. TTM revenue is $724M. Their stock price is 16 times sales and they are losing money.

So if PRED can make $500M in revenue with strong margins and its market cap was 16 times sales or $8B that would make it's stock price around $24/share. Just something to think about while we are arguing about billions in revenue in the next 2-3 years on 3 products.

This is why I am here. It's not for the stem cells.